Sphera Funds Management Ltd. Buys Johnson & Johnson, Novo Nordisk A/S, Bristol-Myers Squibb Company, Sells Mylan NV, Ituran Location and Control, Celgene Corp

Investment company Sphera Funds Management Ltd. buys Johnson & Johnson, Novo Nordisk A/S, Bristol-Myers Squibb Company, UroGen Pharma, Intercept Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, Novartis AG, Gilead Sciences Inc, AstraZeneca PLC, Biogen Inc, Aerie Pharmaceuticals Inc, Verint Systems Inc, Camtek, Alphabet Inc, MyoKardia Inc, Amazon.com Inc, AnaptysBio Inc, GlaxoSmithKline PLC, CymaBay Therapeutics Inc, SolarEdge Technologies Inc, Macrogenics Inc, SPDR Series Trust Homebuilders, Precision BioSciences Inc, NICE, iShares 20+ Year Treasury Bond ETF, Fiserv Inc, Mohawk Industries Inc, Aeglea BioTherapeutics Inc, Advance Auto Parts Inc, Westinghouse Air Brake Technologies Corp, Allot, AudioCodes, Retrophin Inc, Mellanox Technologies, Radware, ARYA Sciences Acquisition Corp, Microsoft Corp, Palo Alto Networks Inc, Tocagen Inc, Acer Therapeutics Inc, Delek US Holdings Inc, Mersana Therapeutics Inc, Coherus BioSciences Inc, Kornit Digital, GlycoMimetics Inc, VistaGen Therapeutics Inc, ForeScout Technologies Inc, Allena Pharmaceuticals Inc, Magic Software Enterprises, sells Mylan NV, Ituran Location and Control, Celgene Corp, Teva Pharmaceutical Industries, Sage Therapeutics Inc, Reata Pharmaceuticals Inc, Axovant Gene Therapies, GW Pharmaceuticals PLC, Merck Inc, Viking Therapeutics Inc, bluebird bio Inc, Immunomedics Inc, argenx SE, Sarepta Therapeutics Inc, Epizyme Inc, uniQure NV, PTC Therapeutics Inc, Scholar Rock Holding Corp, Sangamo Therapeutics Inc, Evoke Pharma Inc, SPDR Series Trust S&P Biotech, Agios Pharmaceuticals Inc, AC Immune SA, Portola Pharmaceuticals Inc, Global Blood Therapeutics Inc, Translate Bio Inc, ProQR Therapeutics NV, Zafgen Inc, Abeona Therapeutics Inc, Aerpio Pharmaceuticals Inc, Pieris Pharmaceuticals Inc, Array BioPharma Inc, Arqule Inc, Biohaven Pharmaceutical Holding Co, Molecular Templates Inc, Apellis Pharmaceuticals Inc, Urovant Sciences, CytomX Therapeutics Inc, Dova Pharmaceuticals Inc, Melinta Therapeutics Inc, Clearside Biomedical Inc, Idera Pharmaceuticals Inc, Arvinas Inc, Corvus Pharmaceuticals Inc, Savara Inc, Verrica Pharmaceuticals Inc, Kezar Life Sciences Inc, MeiraGTx Holdings PLC, Sierra Oncology Inc, Adverum Biotechnologies Inc, Constellation Pharmaceuticals Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Sphera Funds Management Ltd.. As of 2019Q1, Sphera Funds Management Ltd. owns 98 stocks with a total value of $1.1 billion. These are the details of the buys and sells.

• New Purchases: JNJ, NVO, URGN, ICPT, NVS, BIIB, AERI, CAMT, MYOK, GOOGL, AMZN, ANAB, CBAY, SEDG, MGNX, XHB, DTIL, NICE, TLT, FISV, AAP, WAB, AUDC, RDWR, ARYA, TOCA, ACER, MRSN, DK, CHRS, MGIC,
• Added Positions: BMY, ALXN, GILD, AZN, VRNT, GSK, MHK, AGLE, ALLT, RTRX, MLNX, MSFT, PANW, ASND, XENE, VTGN, GLYC, KRNT, FSCT, ALNA, FOLD, KRYS, SBBP, GILT, CSTE,
• Reduced Positions: MYL, CELG, TEVA, RETA, AXGT, MRK, BLUE, IMMU, ARGX, SRPT, QURE, PTCT, GBT, PRQR, ARQL, BHVN, ALDX, CTMX, NERV, ARVN, CRVS, OSMT, MGTX, AUTL, CNST,
• Sold Out: ITRN, SAGE, GWPH, VKTX, EPZM, SRRK, SGMO, EVOK, XBI, AGIO, ACIU, PTLA, TBIO, ARPO, ZFGN, ABEO, PIRS, ARRY, MTEM, APLS, UROV, DOVA, CLSD, MLNT, IDRA, SVRA, VRCA, KZR, SRRA, ADVM,

For the details of SPHERA FUNDS MANAGEMENT LTD.'s stock buys and sells, go to https://www.gurufocus.com/guru/sphera+funds+management+ltd./current-portfolio/portfolio

These are the top 5 holdings of SPHERA FUNDS MANAGEMENT LTD.

1. SPDR Series Trust S&P Biotech (XBI) - 3,335,000 shares, 27.56% of the total portfolio.
2. Bristol-Myers Squibb Company (BMY) - 879,900 shares, 3.83% of the total portfolio. Shares added by 39.67%
3. Johnson & Johnson (JNJ) - 265,000 shares, 3.38% of the total portfolio. New Position
4. Amicus Therapeutics Inc (FOLD) - 2,488,078 shares, 3.09% of the total portfolio. Shares added by 1.64%
5. Alexion Pharmaceuticals Inc (ALXN) - 247,300 shares, 3.05% of the total portfolio. Shares added by 47.11%

New Purchase: Johnson & Johnson (JNJ)

Sphera Funds Management Ltd. initiated holding in Johnson & Johnson. The purchase prices were between $125.72 and $139.79, with an estimated average price of $133.86. The stock is now traded at around $141.70. The impact to a portfolio due to this purchase was 3.38%. The holding were 265,000 shares as of .

New Purchase: Novo Nordisk A/S (NVO)

Sphera Funds Management Ltd. initiated holding in Novo Nordisk A/S. The purchase prices were between $46.07 and $52.63, with an estimated average price of $49.1. The stock is now traded at around $51.90. The impact to a portfolio due to this purchase was 1.91%. The holding were 400,000 shares as of .

New Purchase: UroGen Pharma Ltd (URGN)

Sphera Funds Management Ltd. initiated holding in UroGen Pharma Ltd. The purchase prices were between $35.47 and $54.55, with an estimated average price of $42.07. The stock is now traded at around $35.92. The impact to a portfolio due to this purchase was 1.04%. The holding were 308,377 shares as of .

New Purchase: Intercept Pharmaceuticals Inc (ICPT)

Sphera Funds Management Ltd. initiated holding in Intercept Pharmaceuticals Inc. The purchase prices were between $91.83 and $120.68, with an estimated average price of $109.22. The stock is now traded at around $84.15. The impact to a portfolio due to this purchase was 1.02%. The holding were 100,000 shares as of .

New Purchase: Novartis AG (NVS)

Sphera Funds Management Ltd. initiated holding in Novartis AG. The purchase prices were between $73.8 and $84.4, with an estimated average price of $78.6. The stock is now traded at around $93.24. The impact to a portfolio due to this purchase was 0.88%. The holding were 100,000 shares as of .

New Purchase: Aerie Pharmaceuticals Inc (AERI)

Sphera Funds Management Ltd. initiated holding in Aerie Pharmaceuticals Inc. The purchase prices were between $36.1 and $49.25, with an estimated average price of $43.86. The stock is now traded at around $33.25. The impact to a portfolio due to this purchase was 0.65%. The holding were 150,000 shares as of .

Added: Bristol-Myers Squibb Company (BMY)

Sphera Funds Management Ltd. added to a holding in Bristol-Myers Squibb Company by 39.67%. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $49.11. The impact to a portfolio due to this purchase was 1.09%. The holding were 879,900 shares as of .

Added: Alexion Pharmaceuticals Inc (ALXN)

Sphera Funds Management Ltd. added to a holding in Alexion Pharmaceuticals Inc by 47.11%. The purchase prices were between $97.36 and $137.75, with an estimated average price of $123.89. The stock is now traded at around $128.70. The impact to a portfolio due to this purchase was 0.98%. The holding were 247,300 shares as of .

Added: Gilead Sciences Inc (GILD)

Sphera Funds Management Ltd. added to a holding in Gilead Sciences Inc by 37.14%. The purchase prices were between $62.53 and $70.05, with an estimated average price of $66.46. The stock is now traded at around $69.09. The impact to a portfolio due to this purchase was 0.77%. The holding were 480,000 shares as of .

Added: AstraZeneca PLC (AZN)

Sphera Funds Management Ltd. added to a holding in AstraZeneca PLC by 35.92%. The purchase prices were between $35.49 and $43.02, with an estimated average price of $39.37. The stock is now traded at around $41.86. The impact to a portfolio due to this purchase was 0.68%. The holding were 700,000 shares as of .

Added: Verint Systems Inc (VRNT)

Sphera Funds Management Ltd. added to a holding in Verint Systems Inc by 77.01%. The purchase prices were between $40.65 and $59.86, with an estimated average price of $49.79. The stock is now traded at around $55.72. The impact to a portfolio due to this purchase was 0.63%. The holding were 263,926 shares as of .

Added: GlaxoSmithKline PLC (GSK)

Sphera Funds Management Ltd. added to a holding in GlaxoSmithKline PLC by 38.71%. The purchase prices were between $37.83 and $41.87, with an estimated average price of $39.95. The stock is now traded at around $40.97. The impact to a portfolio due to this purchase was 0.46%. The holding were 430,000 shares as of .

Sold Out: Ituran Location and Control Ltd (ITRN)

Sphera Funds Management Ltd. sold out a holding in Ituran Location and Control Ltd. The sale prices were between $31.01 and $37.86, with an estimated average price of $34.09.

Sold Out: Sage Therapeutics Inc (SAGE)

Sphera Funds Management Ltd. sold out a holding in Sage Therapeutics Inc. The sale prices were between $89.33 and $163.65, with an estimated average price of $144.22.

Sold Out: GW Pharmaceuticals PLC (GWPH)

Sphera Funds Management Ltd. sold out a holding in GW Pharmaceuticals PLC. The sale prices were between $97.39 and $177.34, with an estimated average price of $147.85.

Sold Out: Viking Therapeutics Inc (VKTX)

Sphera Funds Management Ltd. sold out a holding in Viking Therapeutics Inc. The sale prices were between $7.58 and $9.94, with an estimated average price of $8.38.

Sold Out: Epizyme Inc (EPZM)

Sphera Funds Management Ltd. sold out a holding in Epizyme Inc. The sale prices were between $5.98 and $13.98, with an estimated average price of $11.1.

Sold Out: Scholar Rock Holding Corp (SRRK)

Sphera Funds Management Ltd. sold out a holding in Scholar Rock Holding Corp. The sale prices were between $14.24 and $22.97, with an estimated average price of $17.67.

Reduced: Mylan NV (MYL)

Sphera Funds Management Ltd. reduced to a holding in Mylan NV by 40.24%. The sale prices were between $26.01 and $32.1, with an estimated average price of $29.18. The stock is now traded at around $18.51. The impact to a portfolio due to this sale was -2.13%. Sphera Funds Management Ltd. still held 1,002,307 shares as of .

Reduced: Celgene Corp (CELG)

Sphera Funds Management Ltd. reduced to a holding in Celgene Corp by 46.24%. The sale prices were between $64.09 and $94.34, with an estimated average price of $87.12. The stock is now traded at around $98.48. The impact to a portfolio due to this sale was -1.59%. Sphera Funds Management Ltd. still held 250,000 shares as of .

Reduced: Teva Pharmaceutical Industries Ltd (TEVA)

Sphera Funds Management Ltd. reduced to a holding in Teva Pharmaceutical Industries Ltd by 92.36%. The sale prices were between $15.42 and $20.01, with an estimated average price of $17.62. The stock is now traded at around $8.41. The impact to a portfolio due to this sale was -1.15%. Sphera Funds Management Ltd. still held 53,834 shares as of .

Reduced: Reata Pharmaceuticals Inc (RETA)

Sphera Funds Management Ltd. reduced to a holding in Reata Pharmaceuticals Inc by 63.05%. The sale prices were between $51.9 and $101.79, with an estimated average price of $82.55. The stock is now traded at around $87.21. The impact to a portfolio due to this sale was -0.9%. Sphera Funds Management Ltd. still held 81,769 shares as of .

Reduced: Axovant Gene Therapies Ltd (AXGT)

Sphera Funds Management Ltd. reduced to a holding in Axovant Gene Therapies Ltd by 92.21%. The sale prices were between $7.68 and $14.16, with an estimated average price of $9.89. The stock is now traded at around $5.81. The impact to a portfolio due to this sale was -0.87%. Sphera Funds Management Ltd. still held 638,542 shares as of .

Reduced: Merck & Co Inc (MRK)

Sphera Funds Management Ltd. reduced to a holding in Merck & Co Inc by 20.13%. The sale prices were between $72.92 and $83.17, with an estimated average price of $78.33. The stock is now traded at around $85.99. The impact to a portfolio due to this sale was -0.84%. Sphera Funds Management Ltd. still held 377,000 shares as of .

Here is the complete portfolio of SPHERA FUNDS MANAGEMENT LTD.. Also check out:

1. SPHERA FUNDS MANAGEMENT LTD.'s Undervalued Stocks
2. SPHERA FUNDS MANAGEMENT LTD.'s Top Growth Companies, and
3. SPHERA FUNDS MANAGEMENT LTD.'s High Yield stocks
4. Stocks that SPHERA FUNDS MANAGEMENT LTD. keeps buying